Issues in rheumatoid arthritis-Reference-Cited by-同舟云学术

Issues in rheumatoid arthritis

Published:1999-04 Issue:9159 Volume:353 Page:1186
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Emery P,Smolen J

Publisher

Elsevier BV

Subject

General Medicine

Reference5 articles.

1. Placebo-controlled studies in rheumatoid arthritis: ethical issues;Stein;Lancet,1999

2. An anatomical explanation for goodprognosis rheumatoid arthritis;McGonagle;Lancet,1999

3. Rheumatoid arthritis not yet curable with early aggressive therapy;Emery;Lancet,1997

4. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial;Smolen;Lancet,1999

5. X-ray analysis of 12 months treatment of active rheumatoid arthritis with leflunomide compared to placebo or methotrexate;Schiff;Arthritis Rheum,1998

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estudio descriptivo de la utilización de los FAMES en los pacientes con artritis reumatoide o artritis persistente que inician tratamiento farmacológico en España. (ESTUDIO FIRST);Reumatología Clínica;2011-03

2. Descriptive study of the use of DMARD in patients with Rheumatoid arthritis or persistent arthritis who start drug treatment in Spain (FIRST);Reumatología Clínica (English Edition);2011-01

3. The burden of rheumatoid arthritis and access to treatment: a medical overview;The European Journal of Health Economics;2007-12-21

4. Ethical aspects of new medicines targeted at treatment of RA;Annals of the Rheumatic Diseases;2001-03-01

5. Re: High Frequency of Multiple Melanomas and Breast and Pancreas Carcinomas in CDKN2A Mutation-Positive Melanoma Families;JNCI Journal of the National Cancer Institute;2001-02-21